BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35864071)

  • 1. Survival analysis of 80 elderly patients with esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy with S-1.
    Ran JJ; Shen JJ; Ma J; Li XY
    Cancer Radiother; 2022 Nov; 26(8):1064-1069. PubMed ID: 35864071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J; Yin W; Yao H; Gu W
    Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for 495 nonoperative esophageal squamous cancer patients receiving IMRT plus chemotherapy: A retrospective analysis.
    Gao Q; Liu ZY; Cheng Y; Di XK; Zhang YM; Sun XC; Xia XJ; Ge XL
    Cancer Radiother; 2022 Nov; 26(8):1002-1007. PubMed ID: 35933288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
    Modesto A; Dalmasso C; Lusque A; Vieillevigne L; Izar F; Moyal E; Carrère N; Guimbaud R; Rives M
    Cancer Radiother; 2020 Apr; 24(2):88-92. PubMed ID: 32156457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities.
    Chen NB; Qiu B; Zhang J; Qiang MY; Zhu YJ; Wang B; Guo JY; Cai LZ; Huang SM; Liu MZ; Li Q; Hu YH; Li QW; Liu H
    Cancer Res Treat; 2020 Jan; 52(1):31-40. PubMed ID: 31048664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
    Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
    Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
    Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT.
    Xiang G; Xu C; Chai G; Lyu B; Li Z; Wang B; Shi M; Zhao L
    Radiat Oncol; 2023 Jul; 18(1):114. PubMed ID: 37430276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
    Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
    Ren XJ; Wang L; Han C; Liu LL
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey.
    Li C; Wang X; Wang L; Chen J; Zhang W; Pang Q; Zhao Y; Sun X; Zhang K; Li G; Li L; Qiao X; Liu M; Wang Y; Deng L; Wang W; Bi N; Zhang T; Deng W; Ni W; Chang X; Han W; Zhou Z; Liang J; Feng Q; Wang L; Chen D; Lv J; Zhu S; Han C; Xiao Z
    Acta Oncol; 2021 May; 60(5):627-634. PubMed ID: 33793382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
    Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
    Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
    Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
    Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma.
    Ge X; Yang X; Lu X; Wen W; Zhen F; Ye H; Zhu H; Cao Y; Zhang S; Cheng H; Ma J; Yang B; Dai S; Guo Q; Cai J; Sun X
    Tumori; 2015; 101(2):168-73. PubMed ID: 25791535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
    Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
    Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy.
    Qiu J; Yang J; Yu Y; Wang Z; Lin H; Ke D; Zheng H; Li J; Yao Q
    BMC Cancer; 2023 Jun; 23(1):597. PubMed ID: 37380982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
    Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
    Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma.
    Xia X; Liu Z; Cai B; Di X; Sun X; Ge X
    Cancer Radiother; 2021 Feb; 25(1):39-44. PubMed ID: 33419607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience.
    Xu Y; Wang Z; Liu G; Zheng X; Wang Y; Feng W; Lai X; Zhou X; Li P; Ma H; Wang J; Hu X; Chen M
    J Cancer Res Ther; 2016 Oct; 12(Supplement):82-88. PubMed ID: 27721262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.